Fagron NV
OTC:ARSUF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.9), the stock would be worth $23.97 (10% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.2 | $26.53 |
0%
|
| 3-Year Average | 2.9 | $23.97 |
-10%
|
| 5-Year Average | 2.9 | $24.59 |
-7%
|
| Industry Average | 3.5 | $28.92 |
+9%
|
| Country Average | 1.1 | $9.53 |
-64%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| BE |
|
Fagron NV
OTC:ARSUF
|
1.7B USD | 3.2 | 19.2 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
102.7B USD | -78 | 23.3 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
60.7B USD | 31.8 | 37.4 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.7B USD | 31.5 | 37 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
48.5B USD | -16.5 | 28.6 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
31.6B AUD | 6.5 | 35.1 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.8B CNY | 0.8 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.8B USD | 2.7 | 21.8 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.2B CNY | 2.5 | 20.9 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 6 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.5B HKD | 0.6 | 7.2 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 0.9 |
| Median | 1.1 |
| 70th Percentile | 1.7 |
| Max | 292.9 |
Other Multiples
Fagron NV
Glance View
Fagron NV is a Belgian multinational company that has woven specialized pharmaceutical compounding into the fabric of modern healthcare. Founded in 1990, the company's mission has always been to advance personalized medicine by focusing on the compounding sector, which involves tailoring and mixing pharmaceutical ingredients to produce unique medications tailored to the specific needs of patients. By transforming individual healthcare demands into bespoke pharmaceutical solutions, Fagron serves the global medical community by manufacturing and distributing both active and inactive pharmaceutical ingredients, as well as offering various base products. This strategic positioning not only supports healthcare professionals and pharmacies in delivering specialized patient care but also fortifies the company's commitment to improving global health outcomes. The key to Fagron's business model lies in its adept integration of innovation alongside therapeutic and technological solutions, ensuring they maintain a strong presence within the compounding market. The company particularly thrives on its ability to address niches in the pharmaceutical industry, ones often overlooked by large pharma entities due to scale inefficiencies. Through its three principal segments—Pharmaceutical Compounding, Raw Materials, and Innovative Concepts—Fagron generates revenue by supplying pharmacies and medical institutions worldwide, from small community pharmacies to large hospital networks. Its broad portfolio of over 30,000 products caters to a spectrum of needs, fostering both patient-specific and bulk pharmaceutical solutions. By combining quality, safety, and regulatory compliance with a keen market understanding, Fagron NV continues to sustain its role as a crucial player in the personalized medicine arena.